Edit
Adial Pharmaceuticals (NASDAQ: ADIL)
http://www.adialpharma.com/Last activity: 07.05.2025
Active
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company’s landmark ONWARD™ Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. The Company is also developing adenosine analogs for the treatment of pain and other disorders.
Location: United States, Virginia, Charlottesville
Employees: 1-10
Total raised: $2.75M
Founded date: 2010
Investors 1
| Date | Name | Website |
| - | UVA Licens... | lvg.virgin... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.05.2025 | - | $2.75M | - |
Mentions in press and media 15
| Date | Title | Description |
| 07.05.2025 | Adial Pharmaceuticals raises $2.75M | - |
| 16.02.2022 | Adial Pharmaceuticals Announces Closing of $10 Million Financing | CHARLOTTESVILLE, Va., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and preventio... |
| 15.02.2022 | Adial Pharmaceuticals : Announces Pricing of $10 Million Registered Direct Offering - Form 8-K | Adial Pharmaceuticals Announces Pricing of $10 Million Registered Direct Offering CHARLOTTESVILLE, Va., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial" or the "Company"), a cl... |
| 14.02.2022 | ADIAL PHARMACEUTICALS ANNOUNCES PRICING OF $10 MILLION REGISTERED DIRECT OFFERING | CHARLOTTESVILLE, Va. - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ('Adial' or the 'Company'), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disord... |
| 11.02.2022 | Adial Pharmaceuticals Announces Pricing of $10 Million Registered Direct Offering | CHARLOTTESVILLE, Va., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and preventio... |
| 11.02.2022 | Adial Pharmaceuticals Announces Pricing of $10 Million Registered Direct Offering | CHARLOTTESVILLE, Va., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and preventio... |
| 22.12.2021 | Adial Pharmaceuticals Completes Private Placement of Common Stock at $4.00 Per Share | CHARLOTTESVILLE, Va., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and preventio... |
| 11.11.2021 | Adial Pharmaceuticals Announces Private Placement of Common Stock at $4.00 Per Share and Cash Exercise of Stock Options | CHARLOTTESVILLE, Va. - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ('Adial' or the 'Company'), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disord... |
| 10.11.2021 | Adial Pharmaceuticals Announces Private Placement of Common Stock at $4.00 Per Share and Cash Exercise of Stock Options | Financing to support clinical trial pathway for non-opioid drug candidate for treatment of pain CHARLOTTESVILLE, Va., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical... |
| 10.11.2021 | Adial Pharmaceuticals Announces Private Placement of Common Stock at $4.00 Per Share and Cash Exercise of Stock Options | CHARLOTTESVILLE, Va., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and preventio... |
Show more